FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/12/030107 [Registered on: 29/12/2020] Trial Registered Prospectively
Last Modified On: 20/06/2022
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Biological
Ayurveda 
Study Design  Randomized, Parallel Group, Multiple Arm Trial 
Public Title of Study   IMPACT OF VAMANA KARMA(THERAPEUTICALLY INDUCED EMESIS) AND TRIPHALA AND GUDUCHI CHURNA WITH MADHU ON THE MODULATION OF GUT MICROBIOTA. 
Scientific Title of Study   A COMPARATIVE STUDY TO INVESTIGATE THE EFFECT OF VAMANA KARMA AND TRIPHALA AND GUDUCHI CHURNA WITH MADHU ON GUT MICROBIOTA AND METABOLITE PATTERNS IN PRAMEHA W.S.R TO TYPE 2 DIABETES MELLITUS AND HEALTHY INDIVIDUALS. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  NISHANT MALHOTRA 
Designation  M.D SCHOLAR 
Affiliation  ALL INDIA INSTITUTE OF AYURVEDA 
Address  ROOM NO 725 ACADEMIC WING DEPARTMENT OF PANCHAKARMA ALL INDIA INSTITUTE OF AYURVEDA GAUTAMPURI SARITA VIHAR NEW DELHI

South
DELHI
110076
India 
Phone  8130711860  
Fax    
Email  nishantmalhotra9.nm@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DR SANTOSH KUMAR BHATTED 
Designation  ASSOCIATE PROFESSOR  
Affiliation  ALL INDIA INSTITUTE OF AYURVEDA 
Address  ROOM NO 703 ACADEMIC WING DEPARTMENT OF PANCHAKARMA ALL INDIA INSTITUTE OF AYURVEDA GAUTAMPURI SARITA VIHAR NEW DELHI

South
DELHI
110076
India 
Phone  8130711860  
Fax    
Email  santoshbhatted@rediffmail.com  
 
Details of Contact Person
Public Query
 
Name  NISHANT MALHOTRA 
Designation  M.D SCHOLAR 
Affiliation  ALL INDIA INSTITUTE OF AYURVEDA 
Address  ROOM NO 725 ACADEMIC WING DEPARTMENT OF PANCHAKARMA ALL INDIA INSTITUTE OF AYURVEDA GAUTAMPURI SARITA VIHAR NEW DELHI


DELHI
110076
India 
Phone  8130711860  
Fax    
Email  nishantmalhotra9.nm@gmail.com  
 
Source of Monetary or Material Support  
All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi-110076 
AYUSH support to CSIR-IGIB as CoE Grant 
 
Primary Sponsor  
Name  All India Institute of Ayurveda 
Address  Gautampuri, Sarita Vihar, New Delhi-110076 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
CoE at CSIR IGIB  CSIR-IGIB, Sukhdev Vihar, Mathura Road, New Delhi 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
NISHANT MALHOTRA  All India Institute of Ayurveda  OPD No. 6, Department of Panchakarma, Gautampuri, Sarita Vihar, New Delhi
South
DELHI 
8130711860

nishantmalhotra9.nm@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 2  
Name of Committee  Approval Status 
Institutional Ethics Committee- All India Institute of Ayurveda  Approved 
Institutional Ethics Committee- All India Institute of Ayurveda  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied
Modification(s)  
Health Type  Condition 
Healthy Human Volunteers  Healthy individuals as per Proforma for Health Assessment by self-reporting of CSIR Ayurgenomics Unit- TRISUTRA CSIR-IGIB, NEW DELHI 
Patients  (1) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications, (2) ICD-10 Condition:E119||Type 2 diabetes mellitus without complications. Ayurveda Condition: PRAMEHAH,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Triphala and Guduchi Churna with Madhu in Prameha Individuals W.S.R to Type 2 Diabetes Mellitus.  1. Triphala Churna- 3gm with 3gm Madhu 2. Guduchi Churna- 3gm with 3gm Madhu for 30days 
Comparator Agent  Vamana Followed by Triphala and Guduchi Churna with Madhu in Healthy Individuals  1. Vamana Karma(therapeutically induced emesis for internal bio-cleansing) followed by 2. Triphala Churna 3gm with 3gm Madhu 3. Guduchi Churna 3gm with 3gm Madhu 
Intervention  Vamana Followed by Triphala and Guduchi Churna with Madhu in Prameha Individuals W.S.R to Type 2 Diabetes Mellitus  1. Vamana Karma(therapeutically induced emesis for internal bio-cleansing) Followed by 2. Triphala Churna- 3gm with 3gm Madhu for 15 days 3. Guduchi Churna-3gm with 3gm Madhu for 15 days 
 
Inclusion Criteria
Modification(s)  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  For Prameha(Type 2 Diabetes Mellitus) Individuals-
1. BMI≥ 20
2. Kaphaj/Kapha-pittaj Vikriti predominant individuals
3. Diagnosed cases of Prameha/Madhumeha/T2DM with either of the following-
a) Fasting plasma glucose values of ≥ 7.0 mmol/L (126 mg/dl)
b) 2-h post-load plasma glucose ≥ 11.1 mmol/L (200 mg/dl)
c) HbA1c ≥ 6.5% (48 mmol/mol)
d) Random blood glucose ≥ 11.1 mmol/L (200 mg/dl)
4. Chronicity: Up to 10 years
For Healthy Individuals
1. BMI≥ 20
2. Kaphaj/Kapha-pittaj Prakriti predominant Individuals as per Proforma for Prakriti Assessment by CSIR Ayurgenomics Unit- TRISUTRA CSIR-IGIB, NEW DELHI
3. Healthy individuals as per Proforma for Health Assessment by self-reporting of CSIR Ayurgenomics Unit- TRISUTRA CSIR-IGIB, NEW DELHI 
 
ExclusionCriteria 
Details  Patients unfit for Snehana(Internal Oleation), Svedana(Sudation), Vamana(therapeutically induced emesis for internal bio-cleansing).
For Prameha(Type 2 Diabetes Mellitus)-
1. Patients with T2 DM exceeding the following plasma glucose limits-
a) Fasting plasma glucose values of ≥ 300mg/dL
b) 2-h post-load plasma glucose≥400mg/dL
c) Random blood glucose≥ 400mg/dL
2. Chronicity: More than 10 years.
3. Known cases of Severe systemic diseases like- Cardiac disease, pulmonary tuberculosis, severe lung disease, uncontrolled diabetes and pregnant women.
 
 
Method of Generating Random Sequence   Random Number Table 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Reduction in Sign and Symptoms of Prameha(T2DM)patients(By questionnaire Scoring Pattern).
To see the impact of Classical Vamana karma followed by administration of Triphala and Guduchi Churna with Madhu on gut microbiota diversity and metabolite patterns in Prameha (w.s.r Type 2 Diabetes Mellitus). 
56-68 days 
 
Secondary Outcome  
Outcome  TimePoints 
Whole microbiome and metabolome Analysis of both Prameha and healthy individuals to see the impact of classical Vamana karma on Gut Microbiome and metabolomes.
To evaluate change in Plasma Glucose level in the patients of Prameha (w.s.r T2 DM).
To see improvement in the quality of life. 
56-68days 
 
Target Sample Size   Total Sample Size="45"
Sample Size from India="45" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   01/01/2021 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="10"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Closed to Recruitment of Participants 
Recruitment Status of Trial (India)  Closed to Recruitment of Participants 
Publication Details   Will be published in a peer-reviewed journal after the completion of the research work with the prior approval from the competent authority 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

This is a comparative study to investigate the effect of Vamana Karma and Triphala Churna and Guduchi Churna with Madhu on the gut microbiota and metabolite patterns in Prameha W.S.R to Type 2 Diabetes Mellitus and Healthy Individuals as well as to compare the effect of Vamana Karma followed by administration of Triphala Churna and Guduchi Churna with Madhu and administration of Only Triphala Churna and Guduchi Churna with Madhu  in the patients of Prameha W.S.R Type 2 Diabetes Mellitus.


Diet and lifestyle modification being an integral part of Vamana Karma(therapeutic emesis for internal bio-cleansing) may lead to the modification of environmental microflora in a positive aspect for shaping the healthy human microbiota composition thus leading to the state of wellness. This whole information gives a lead that Vamana therapy aims at modulating the gut functioning and thereby restoring the state of homeostasis, improving digestion and metabolism in turn proved to be an effective treatment modality in many diseased conditions like Rheumatoid arthritis, skin disease, Type 2 diabetes mellitus, allergic conditions etc. Therefore, this study can investigate the role of classical Vamana therapy as described in Ayurveda by showing its impact in the modulation of dysbiosis and hence it can emerge as a proven modality of treatment in variety of metabolic, immune mediated, neuropsychiatric and musculo-skeletal diseased conditions.


The study contains the following three groups-


  1. Group 1- Prameha Patients (Vamana Karma followed by Triphala and Guduchi Churna with madhu)- 15 subjects
  2. Group 2- Prameha Patients (Administration of only Triphala and Guduchi Churna with madhu)- 15 subjects
  3. Group 3 - Healthy Individuals (Vamana Karma followed by Triphala and Guduchi Churna with madhu)- 15 subjects


The above mentioned three groups have been taken with an objective to compare the effect of Vamana Karma followed by Triphala Churna and Guduchi Churna with Madhu and administration of only Triphala Churna and Guduchi Churna with Madhu in the patients of Prameha W.S.R to Type 2 Diabetes Mellitus with respect to change in Sign and symptoms, Plasma Glucose Level and gut Microbiota and metabolite patterns i.e Group 1 and Group 2. 


It will also compare the alterations being seen on the gut microbiota and metabolite patterns in both the Prameha and Healthy Individuals undergoing Vamana Karma followed by administration of Triphala and Guduchi churna with Madhu i.e Group 1 and Group 3.


RESEARCH QUESTION

  • Is there any difference in the efficacy of Vamana Karma followed by Triphala and Guduchi Churna with Madhu and direct administration of Triphala and Guduchi Churna with Madhu in the management of Prameha(T2DM).
  • Is there any difference in the impact of classical Vamana Karma followed by Triphala and Guduchi Churna with Madhu on the alteration of Gut Microbiota diversity and metabolite patterns in the patients of Prameha(T2DM) and healthy individuals as well as in the administration of direct Triphala and Guduchi Churna with Madhu in the patients of Prameha(T2DM) only.

HYPOTHESIS

There is significant difference in the efficacy of Vamana Karma followed by Triphala and Guduchi Churna with Madhu as compared to direct administration of Triphala and Guduchi Churna with Madhu in the management of Prameha.

There is significant difference in the impact of classical Vamana karma followed by Triphala and Guduchi Churna with Madhu on the alteration of Gut Microbiota diversity and metabolite patterns in the patients of Prameha(T2DM) and healthy individuals as well as in the administration of direct Triphala and Guduchi Churna with Madhu in the patients of Prameha(T2DM) only.


OBJECTIVES OF THE RESEARCH PROJECT:


PRIMARY:

  1. To compare the efficacy of Vamana Karma followed by administration of Triphala and Guduchi Churna with Madhu and administration of only Triphala and Guduchi Churna with Madhu in the management of Prameha(w.s.r to T2 DM).
  2. To see the impact of Classical Vamana karma followed by administration of Triphala and Guduchi Churna with Madhu on gut microbiota diversity and metabolite patterns in Prameha (w.s.r Type 2 Diabetes).

SECONDARY:

  1. Whole microbiome and metabolome Analysis of both Prameha and healthy individuals to see the impact of classical Vamana karma on Gut Microbiome and metabolomes.
  2. To evaluate change in Plasma Glucose level in the patients of Prameha (w.s.r T2 DM).
  3. To improve the quality of life.

METHODOLOGY-


TYPE OF STUDY DESIGN

  • Experimental Study
  • Triple armed controlled clinical trial.


SAMPLE SIZE CALCULATION


This type of study is being done first time and further the experimental procedures and tests are costly. Therefore, seeing the feasibility we have decided to take 15 individuals in each group.

  1. Group 1- Prameha Patients- (Vamana Karma followed by Triphala and Guduchi Churna with madhu)- 15 Subjects
  2. Group 2- Prameha Patients(Administration of only Triphala and Guduchi Churna with madhu)- 15 Subjects
  3. Group 3-Healthy Individuals (Vamana Karma followed by Triphala and Guduchi Churna with madhu)- 15 Subjects

Total Sample Size = 45

SAMPLE COLLECTION -

Cases (group 1 and group 2) will be recruited attending the OPD& IPD of AIIA, fulfilling the diagnostic criteria as per WHO latest guidelines for T2DM and Clinical Proforma for madhumeha(T2DM) of CSIR Ayurgenomics Unit- TRISUTRA CSIR-IGIB, NEW DELHI

The subjects will be allocated to above 2 groups by randomisation. The 30 random numbers will be picked from random number table. The odd numbers will be allocated to Group A and even numbers to Group B and will receive their respective treatments.

Controls (group 3) will be recruited as per Proforma for Health Assessment by self-reporting  and Prakriti Assessment Proforma of CSIR Ayurgenomics Unit- TRISUTRA CSIR-IGIB, NEW DELHI.


DRUG DELIVERY REGIMEN (DRUG, DOSE DURATION, FOLLOW-UP, WITHDRAWAL)


In Group 1 and 3-

Stepwise administration of-

1. Deepana-Pachana

  • Shunthi churna - 3gm BiD
  • Nagarmotha churna -  3gm BiD

For 3-7 Days until samyaka langhana lakshanas are observed

2. Snehapana-

Murchita-Goghritam (Aarohana krama i.e in increasing dose starting from 40 ml)

For 3-7 days until samyaka snigdha lakshanas are observed

3. Abhayangam– 

With Tila Taila (Q.S)- For 30-35 minutes


For 1 Days and on the day of Vamana

4. Swedanam

Dashmulakwath sarvang mridu bashpa sweda(whole body sudation with Dashmula kwath till samyak swinna lakshanas are observed)

For 1 Days and on the day of Vamana

5. Vamana

  1. Madanaphala-phala-pippali churna= 6gm(Antarnakhmushti pramana)Soaked in Yashtimadhu kashaya overnight
  2. Saindhav = 2.5gm
  3. Madhu = Q.S
  4. Yashti Kashaya = 150ml

            After aakantha-yavagu-pana/dugdhapana(complete filling of stomach with gruel or milk)

For a single time and day

6. Samsarjan karma

 A systematised and gradual administration of wholesome diet plan 

For 3-7 days depending upon Vamana vega(frequency of purgations).


7. Oral Administration of Triphala and Guduchi Churna with Madhu

  • Triphala Churna(3gm) mixed with madhu(3gm) - BiD (before food)
  • Guduchi Churna(3gm) mixed with madhu(3gm) – BiD (after food) 

For 15 days

In Group 2

  • Oral Administration of Triphala and Guduchi Churna with Madhu
    1. Triphala Churna(3gm) mixed with madhu(3gm) - BiD (before food)
    2. Guduchi Churna(3gm) mixed with madhu(3gm) – BiD (after food) 

For 30 days

Total no. of Days treatment given

Total number of days for Group 1 and Group 3 (with an average of Deepana-Pachana , Snehana , Abhyanga, SwedanaVamana and Samsarjan krama is 11-23 Days ) + (Triphala-Guduchi Churna with madhu â€“ 15 days) = Between 26-38 days

In Group 2

  • Oral Administration of Triphala and Guduchi Churna : for 30 days 

Total number of days for Group 2 = 30 Days

Follow-up Period- 


At 15th day and 30th day after completion of treatment


PARAMETER FOR ASSESSMENT OF STUDY OUTCOMES


  • Reduction in Sign and Symptoms of Prameha(T2DM)patients(By questionnaire Scoring Pattern).
  • Microbiota and metabolite analysis of faecal matter, oral swab and vomitus sample through 16s rRNA technology.
  • Plasma Glucose level through intravenous blood sample of the patients.
  • QOL Questionnaire 

Collection of specimens

  • Faecal Sample
  • Oral swab
  • Vomitus sample*
  • Blood Sample*

*Note- Vomitus and Blood sample(for molecular analysis simultaneously along with the blood sample to be collected for Plasma Glucose level test) will also be collected for future analysis if resources and time would allow.

RESPONSE CALCULATION AND ASSESSMENT OF RESPONSE:

The primary outcome measure of this study is to determine the response (R) of the patients to the therapy and it is proposed to be measured in terms of the -

  • Reduction in sign and symptoms of prameha and plasma glucose levels.
  • Absence/reduction in the microbiota and metabolites associated with Type 2 Diabetes Mellitus and which are not beneficial for metabolism.
  • Presence/increase in microbiota and metabolites helping in the prevention of T2DM and which are beneficial for metabolism.
 
Close